BlueSky Vaccines

Next generation virotherapy against cancer

About us

Our mission

The mission of BlueSky Vaccines is to fully exploit the potential of virotherapy against cancer. The focus of the company is on the development of next generation cancer vaccines based on its proprietary viral vector technology platform. Unique properties of the vector lead to an induction of a strong immune response that is capable of overcoming the immunosuppression created by cancers.

Team News & Events Contact us

Team

card image

Thomas Muster

CEO

Over 20 years biotech experience; more than 50 publications; 30 patents; has developed vaccines licensed to Baxter and Boehringer


● Vivaldi Biosciences
● AVIR Green Hills Technology AG
● Mount Sinai School of Medicine

card image

Michael Tscheppe

CFO

Over 20 years in finance, business administration & marketing; university lecturer


● Nuvonis Technologies
● AVIR Green Hills Technology AG
● University of Applied Sciences
● Post AG

card image

Markus Wolschek

CSO

Lead scientist; virology, genetic-engineering and product development expert, more than 30 publications and several patents


● AVIR Green Hills Technology AG
● Medical University Vienna

card image

Manfred Reiter

CTO

More than 20 years as Senior Vice President in the vaccine business; cell bank, process development and manufacturing expert


● Nuvonis Technologies
● Hookipa Biotech
● Baxter Bioscience
● Immuno AG

card image

Joachim Seipelt

COO

PhD in Biochemistry, expert in biotech project evaluation, management and funding, cooperation and licensing, university lecturer


● Nuvonis Technologies
● Austria Wirtschaftsservice
● AVIR Green Hills Technology AG
● Max F. Perutz Laboratories
● Medical University Vienna

Advisory board

Ruediger Herrmann (McDermot Will & Emery)
Noel Barrett (Baxter Vaccines)
Josef Poandl (Investor)

Technology

The vector technology combines a conventional vaccine approach (induction of immunity) with an oncolytic approach (specifically destroying cancer cells). It induces a high level of interferon and triggers an TH1-type immune response, activating both innate and adaptive immunity within the tumor bed. Specifically, the vaccine creates a cytokine environment that leads to:

Shift of the cytokine environment from immunosuppressive (TH2) to immune active (TH1).

Inhibition of immunosuppressive regulatory T-cells (Treg).

Activation of natural killer cells (NK).

Activation of cytotoxic T-cells (CTL).

Activation of dendritic cells (DC).

Pipeline

As first target indication for clinical evaluation of the vector, we have chosen human papillomavirus (HPV)-induced cancers. For this purpose, we effectively expressed the HPV-derived tumor antigens E6 and E7 by the delNS106 vector. The resulting delNS106/E6E7 vaccine has demonstrated excellent results and dose-dependent tumor reduction in animal models. Based on the superior data in animal models, this product will now be tested in a clinical phase I setting in HPV infected individuals. Subsequently, phase II trials against cervical lesions, cervical cancer and head and neck cancer will be performed.

News & Events

Funding

We thank for fundung:

Austria Wirtschaftsservice

FFG

INiTS

Vienna Bussiness Agency

Contact us

Thank you for visiting us. Please keep an eye on our site as we will add new content very soon. In the meantime, let's stay in touch. If you have any question, query or idea, please send us an email.

We'll never share your email with anyone else.